FAST-EU, a pilot initiative that enables an accelerated assessment of multinational clinical trials in the European Union

Last updated: 16 November 2026

For updates, click on the ‘+’ sign below.

DateUpdate(s)
16 Nov 2026The following new sections have been added:
i) Submission Windows (until June 2027)
ii) Extension of the FAST-EU pilot to substantial modifications added.

The section Participating member states and RMS distribution has been updated.


4 Nov 2026New section Participating member states and RMS distribution (November 2026) added.
1 Jul 2026In the section Which reporting member states have been selected for Fast EU until now (1 July 2026)?, Ireland and Latvia have been added.
23 Jun 2026The following updates were made:
i) In the section What should a sponsor do in order to enter a trial into FAST-EU?, specific information for Italy and Spain added.
ii) New section Which Member States are participating in FAST-EU? added.
15 June 2026In the section Which reporting member states have been selected for Fast EU until now, Estonia and Slovenia have been added.
12 May 2026The following sections were updated:
i) What should a sponsor do in order to enter a trial into FAST-EU?
ii) Latest information on the expression of interest availability of slots

The following new section was added:
Which reporting member states have been selected for Fast EU until Now (12 May)?
13 2026Section Latest information on the expression of interest availability of slots updated.
10 Feb 2026New section Latest information on the expression of interest availability of slots added.

This post aims to provide basic information on the FAST-EU initiative. The information is by no means exhaustive.

What is the FAST-Initiative?

FAST-EU (Facilitating and Accelerating Strategic Clinical Trials) is a pilot initiative by the Heads of Medicines Agencies (HMA), the Clinical Trials Coordination Group (CTCG) and MedEthics EU implemented within the framework of the Clinical Trials Regulation (CTR).

Operating within the EU Clinical Trials Regulation and CTIS, FAST-EU offers sponsors a predictable and efficient pathway for initial clinical trial applications.

FAST-EU is part of the comprehensive European strategy to strengthen competitiveness in biomedical research.

  • The procedure provides for clear and ambitious timelines and coordination mechanisms to offer sponsors of clinical trials clearer and shorter assessment and approval periods.
  • In contrast to other regions, the opinions of the ethics committees of all participating member states are already integrated into this ambitious process.
  • The aim is to provide the highest ethical and scientific standards for the clinical profiling of innovative product candidates in Europe.
  • In doing so, the EU is sending out a clear signal in favour of pharmaceutical innovation and increased cooperation between the member states.
Which member states are participating in FAST-EU?

All of the EU Member States except Malta, Luxembourg and Greece. are participating in FAST EU

What is the objective of FAST and how is it achieved?

The objective of FAST-EU is to accelerate the coordinated assessment and authorisation of multinational clinical trial applications by applying ambitious internal coordination timelines and reinforced cooperation between Member States, while fully maintaining scientific, safety and ethical standards

The core feature of FAST-EU is a maximum overall timeline of 10 weeks (70 calendar days) from CTIS submission to final conclusion, including sponsor response times.

  • This is achieved through parallel validation and assessment workflows and a strengthened role of the RMS, while maintaining scientific, safety and ethical standards.
  • Ethics Committee opinions are fully integrated across all participating Member States.
What does FAST-EU offer beyond accelerating individual clinical trials applications?

Beyond accelerating individual clinical trials applications, FAST-EU also functions as a structured learning and evidence-generation exercise.

What is the scope of FAST-EU?

FAST-EU applies to:

  • initial applications for multinational clinical trials involving more than one Member State, and
  • all categories of investigational medicinal products (IMPs),

FAST-EU does not apply to:

  • mono-national clinical trials
  • partial submissions under Article 11 of the CTR
  • resubmissions of previously lapsed, withdrawn, invalid or rejected trials
  • substantial modifications and subsequent additions of Member States
  • combination trials under the COMBINE project
About the FAST-EU pilot commencing 30 January 2026

The pilot is designed to provide practical insights into the feasibility and challenges of the accelerated assessment model, thereby supporting the future implementation of the EU Biotech Act.

Is it a voluntary pilot and can participation be guaranteed?

Yes, FAST-EU is a voluntary pilot with a planned duration of a year and a limited number of applications per month, so participation cannot be guaranteed.

What are the pre-requisites to enter a trial into FAST-EU?
  • multinational clinical trial with several participating Member State Countries (MSCs) in the EU/EEA
  • readiness of the dossier for submission (i.e. the dossier is finalised and ready for submission in CTIS)
What should a sponsor do in order to enter a trial into FAST-EU?
  • To enter a trial that is ready for submission in CTIS into FAST-EU starting from 30 January 2026, sponsors sponsors should express their interest by sending the Expression of Interest Template which can also be found as Annex to the FAST-EU
     Sponsor Guide via e-mail to FAST-EU@hma.eu.
  • A response can be expected within 5 business days.
  • For Italy and Spain please provide the responsible Ethics Committee.
  • The list of Italian Ethics Committees participating in the FAST-EU project is available on the AIFA website and at this link.
  • For the Spanish Ethics Committees please see the AEMPS website at this link (see the section “CEIm adheridos a procedimientos de evaluación acelerada”).
Latest information on the expression of interest availability of slots

Submission windows are provided in the table below. Expression of Interest should indicate whether CTIS submission would be feasible in the first or second half of the relevant month.

MonthSubmission windowResponse
June20-21 May28 May
July22-23 June30 June
August22-23 July30 July
September20-21 August28 August
October22-23 September30 September
November22-23 October30 October
December19-20 November27 November

Use the application form at the link below.

Further useful information is provided at the link below.

Source: HMA

Submission Windows (until June 2027)

MonthSubmission windowResponse 
November 202621-22 October 202629 October 2026
December 202619-20 November 202627 November 2026
January 20279-10  December 202617  December 2026
February 202719-20 January 202727 January 2027
March 202716-17 February 202724 February 2027
April 202716-17 March 202724 March 2027
May 202720-21 April 202728 April 2027
June 202718-19 May 202726 May 2027
Who is the selection of applications into FAST EU done by?

Selection of applications into the FAST-EU pilot is performed by the FAST-EU Selection Committee, which is composed of members of CTCG and MedEthics EU, acting in conjunction with the proposed RMS.

Is there detailed procedural information available on FAST-EU?

Yes, detailed procedural information is provided in the FAST-EU Sponsor Guide.

Which Member States are participating in FAST-EU?

The following Member States are participating in FAST-EU:
AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IT, LT, LV, NL, NO, PL, PT, RO, SE, SI, SK

Participating member states and RMS distribution

Twenty-six Member States and EEA countries are participating in FAST-EU. Reporting Member State distribution reflects the pan-European character of the initiative. RMS roles completed or ongoing include:

  • Italy
  • Denmark
  • the Netherlands
  • Germany (PEI )
  • Finland
  • Poland
  • Sweden
  • Spain
  • Belgium
  • Norway
  • the Czech Republic

The following are planned for upcoming procedures.

  • Romania
  • Hungary
  • Austria
  • Portugal

Source: HMA

Extension of the FAST-EU pilot to substantial modifications

FAST-EU has been extended to include the accelerated assessment of certain substantial modifications.

  • As of 10 November 2026, sponsors can contact the Reporting Member State (RMS) with the intention of submitting substantial modifications falling within the scope of FAST-EU.
  • This applies to substantial modifications related to a conditional approval that are blocking the initiation of a FAST-EU trial.
  • Sponsors should consult the FAST-EU Sponsor Guide for further information on the applicable requirements and procedures.

Source: BfarM